RT Journal Article
T1 Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase‐2 inhibitor and toceranib phosphate
A1 Alonso Miguel, Daniel
A1 Valdivia Lara, Edgar Guillermo
A1 García San José, Paula
A1 Alonso Díez, Ángela
A1 Clares, Irene
A1 Portero Fuentes, Miriam
A1 Peña Fernández, Laura Luisa
A1 Pérez Alenza, María De Los Dolores
AB Canine inflammatory mammary cancer (IMC) is highly malignant, invasive and a therapeutic challenge, because effective medical treatment is still unavailable. This retrospective study compares the efficacy of an oral cyclooxygenase-2 (COX-2) inhibitor combined with toceranib phosphate and oral cyclophosphamide (multi-drug therapy [MT]) with COX-2 inhibitor therapy alone (single-drug therapy [ST]) in dogs diagnosed with secondary IMC. Clinical response, adverse events, overall survival time (OST), disease-free survival (DFS) and time to progression (TTP) were evaluated. Sixteen patients were included, eight received MT and eight receiving ST. Median OST was significantly higher in patients receiving MT (96.0 vs. 37.5 days; p = .046) and in patients with post-surgical rather than non-surgical IMC (86.5 vs. 41.5 days; p = .038). Additionally, median TTP was significantly higher in patients treated with MT (p = .010). In patients with non-surgical IMC, the clinical benefit (CB) was reached in 100% (n = 3) of patients receiving MT and in 33% (n = 1) of those receiving ST; the response duration was significantly longer in MT cases (p = .026). The absence of disease progression at day 30 of treatment was significantly associated with longer OST, DFS and TTP (p = .018, p = .002 and p < .001, respectively). Adverse events occurred more frequently in patients treated with MT compared with ST (p = .026). The MT protocol produced primarily mild to moderate toxicities, which were resolved with supportive care; therefore, the combination of drugs was adequately tolerated by most of the patients. The combination of toceranib, a COX-2inhibitor and oral cyclophosphamide may be a protocol with potential therapeutic efficacy for dogs with IMC.
PB Wiley
SN 1476-5810
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/107253
UL https://hdl.handle.net/20.500.14352/107253
LA eng
NO Alonso-Miguel D, Valdivia G, García-San José P, Alonso-Diez A, Clares I, Portero M, Peña L, Pérez-Alenza MD. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate. Vet Comp Oncol. 2022;20(1): 179-188, doi:10.1111/vco.12760
NO Ministerio de Ciencia, Innovación y Tecnología (España)
NO Universidad Complutense de Madrid
NO Consejo Nacional de Humanidades, Ciencias y Tecnologías (México)
DS Docta Complutense
RD 10 abr 2025